- Form 8 Filing
On October 6, 2022, AngioDynamics, Inc. (“AngioDynamics”) announced that a jury verdict has been rendered in its antitrust action against C.R. Bard, Inc. and Bard Access Systems, Inc.
Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range